1. Search Result
Search Result
Results for "

iron metabolism

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dyes

5

Peptides

3

Inhibitory Antibodies

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-D1533
    RhoNox-1
    35+ Cited Publications

    Fluorescent Dye Others
    RhoNox-1 is a fluorescent probe for the specific detection of divalent iron ions, and when RhoNox-1 reacts with Fe 2+. RhoNox-1 can generate an irreversible orange (red) fluorescent product (Ex/Em:540/575 nm) . FeRhoNox-1 can enter the cell well, suitable for the detection of Fe 2+ in living cells, and tends to be localized in the Golgi apparatus .
    RhoNox-1
  • HY-P99590A
    Sotatercept (mIgG2a)
    1 Publications Verification

    RAP-011

    TGF-β Receptor TGF-beta/Smad Cardiovascular Disease Metabolic Disease
    Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) .
    Sotatercept (mIgG2a)
  • HY-W698249

    Ferroptosis Bacterial Cardiovascular Disease Infection
    Ferrous gluconate is a highly water-soluble iron-containing agent with high bioavailability and bactericidal activity. As a non-heme iron, Ferrous gluconate is used for meat product fortification and improvement of iron deficiency anemia. Ferrous gluconate induces ferroptosis in E. coli through Fe 2+ infiltration, reactive oxygen species burst, lipid peroxidation and direct interaction with DNA. Ferrous gluconate also downregulates the SOS responsive transcriptional repressor LexA. In addition, Ferrous gluconate regulates multiple key pathways in E. coli such as fatty acid metabolism, iron-sulfur cluster assembly and pyruvate metabolism, and is applied in studies related to *E. coli* infection and iron deficiency anemia .
    Ferrous gluconate
  • HY-P99359

    ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)

    TGF-beta/Smad Metabolic Disease
    Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
    Elezanumab
  • HY-DY1030

    Fluorescent Dye Others
    RhoNox-1 (solution) is a fluorescent probe for the specific detection of divalent iron ions, and when RhoNox-1 reacts with Fe 2+. RhoNox-1 can generate an irreversible orange (red) fluorescent product (Ex/Em:540/575 nm). FeRhoNox-1 can enter the cell well, suitable for the detection of Fe 2+ in living cells, and tends to be localized in the Golgi apparatus .
    Solvent and concentration: DMSO: 5 mM
    RhoNox-1 (solution)
  • HY-P1723
    Spexin
    2 Publications Verification

    Neuropeptide Q

    Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy Cardiovascular Disease Neurological Disease
    Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
    Spexin
  • HY-147379

    Ferroportin Metabolic Disease
    Hepcidin antagonist-1 (example 104) is a potent hepcidin (hepcidine) antagonist with an IC50<50 μM. Hepcidin antagonist-1 can be used for researching iron metabolism disorders, such as anemias .
    Hepcidin antagonist-1
  • HY-P3494

    Hepcidin Bacterial Infection Inflammation/Immunology
    Hepcidin-25 (human) is an iron metabolism regulator and Antimicrobial agent. Hepcidin-25 (human) exerts anti-inflammatory and antimicrobial activities by regulating iron-mediated oxidative damage .
    Hepcidin-25 (human)
  • HY-135024

    Phenylacetyl Coenzyme A

    Endogenous Metabolite Metabolic Disease
    Phenylacetyl CoA is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .
    Phenylacetyl CoA
  • HY-150280

    Apoptosis Ferroptosis DNA/RNA Synthesis IRE1 CDK Caspase Drug Derivative Cancer
    Ironomycin is a derivative of Salinomycin (HY-15597). Ironomycin exhibits selective inhibitory activity against mantle cell lymphoma (MCL) cells. Ironomycin blocks the cell cycle and induces apoptosis and ferroptosis. Ironomycin induces double-strand DNA breaks and activates the unfolded protein response (UPR), particularly the IRE1α signaling pathway accumulation. The combination of Ironomycin with Ibrutinib (HY-10997) shows a synergistic effect. Ironomycin can be used for the study of MCL.
    Ironomycin
  • HY-P3494B

    Hepcidin Bacterial Infection Inflammation/Immunology
    Hepcidin-25 (human) TFA is an iron metabolism modulator and Antimicrobial agent. Hepcidin-25 (human) TFA shows anti-inflammatory and anti-bacterial activity via modulation of iron-mediated oxidant injury .
    Hepcidin-25 (human) TFA
  • HY-145965

    Ferroportin Metabolic Disease
    Ferroportin-IN-1 is a ferroportin inhibitor extracted from patent WO2020123850A1 compound 23. Ferroportin-IN-1 can be used for the research of diseases caused by a lack of hepcidin or iron metabolism disorders .
    Ferroportin-IN-1
  • HY-148205A

    Drug Derivative Others
    Trypanothione TFA is a bis-glutathionyl derivative, can be isolated from trypanosomatids. Trypanothione TFA itself or assisted by different enzymatic systems is involved in anti-oxidant defense, cell proliferation, removal of toxic compounds and metabolites and iron-sulfur metabolism .
    Trypanothione TFA
  • HY-P1723A

    Neuropeptide Q TFA

    Neuropeptide Y Receptor Apoptosis Ferroptosis Autophagy Cardiovascular Disease Metabolic Disease
    Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
    Spexin TFA
  • HY-P991137

    Ser/Thr Protease Metabolic Disease
    Exerenibart is an immunoglobulin G4-κ monoclonal antibody targeting human transmembrane serine protease 6 (TMPRSS6). Exerenibart is promising for research of diseases associated with iron metabolism disorders, such as iron overload or iron deficiency .
    Exerenibart
  • HY-W698249R

    Reference Standards Ferroptosis Bacterial
    Ferrous gluconate (Standard) is the analytical standard of Ferrous gluconate. This product is intended for research and analytical applications. Ferrous gluconate is a highly water-soluble iron-containing agent with high bioavailability and bactericidal activity. As a non-heme iron, Ferrous gluconate is used for meat product fortification and improvement of iron deficiency anemia. Ferrous gluconate induces ferroptosis in E. coli through Fe 2+ infiltration, reactive oxygen species burst, lipid peroxidation and direct interaction with DNA. Ferrous gluconate also downregulates the SOS responsive transcriptional repressor LexA. In addition, Ferrous gluconate regulates multiple key pathways in E. coli such as fatty acid metabolism, iron-sulfur cluster assembly and pyruvate metabolism, and is applied in studies related to *E. coli* infection and iron deficiency anemia .
    Ferrous gluconate (Standard)
  • HY-135024A

    Phenylacetyl coenzyme A lithium; S-Benzeneacetate-CoA lithium; S-Benzeneacetate-coenzyme A lithium

    Endogenous Metabolite Metabolic Disease
    Phenylacetyl CoA lithium (Phenylacetyl Coenzyme A lithium) is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica .
    Phenylacetyl CoA lithium
  • HY-157433

    Bacterial Infection
    Mab-SaS-IN-1 (compoud 1H) is Mab-SaS inhibitor with the IC50 of 2 μM. Mab-SaS-IN-1 can be used for study of antibiosis by blocking iron uptake and metabolism .
    Mab-SaS-IN-1
  • HY-149353

    Bacterial Infection
    Antibacterial agent 145 (compound 1b) is an antibacterial agent depending on bacterial iron uptake pathway. Antibacterial agent 145 disrupts cytoplasmic membrane integrity and inhibits cell metabolism but exhibits low cytotoxic effects to normal cells .
    Antibacterial agent 145
  • HY-119325A

    NK433

    Apoptosis Cancer
    Lanperisone hydrochloride is a novel oral muscle relaxant with anticancer activity. Lanperisone hydrochloride produces non-apoptotic cell death by inhibiting monosynaptic and polysynaptic reflex potentials. Lanperisone hydrochloride is also believed to play an important role in the dysregulation of iron metabolism and antioxidant systems to modulate processes associated with ischemic stroke .
    Lanperisone hydrochloride
  • HY-119325

    NK433 free base

    Apoptosis Cancer
    Lanperisone is a novel oral muscle relaxant with anticancer activity. Lanperisone produces non-apoptotic cell death by inhibiting monosynaptic and polysynaptic reflex potentials. Lanperisone is also believed to play an important role in the dysregulation of iron metabolism and antioxidant systems to modulate processes associated with ischemic stroke .
    Lanperisone
  • HY-179052

    Apoptosis Autophagy Bcl-2 Family Caspase Atg8/LC3 Atg7 CDK Reactive Oxygen Species (ROS) Cancer
    Apoptosis inducer 50 (Compound 5e) is an apoptosis inducer as well as an autophagy inducer agent. Apoptosis inducer 50 exhibits potent and selective anti-cancer activity against triple-negative breast cancer cells and metastatic colon cancer cells. Apoptosis inducer 50 upregulates the expression of pro-apoptotic proteins (Bax, Bim, cleaved Caspase-9) and downregulates the expression of the anti-apoptotic protein (BCL-XL). Apoptosis inducer 50 upregulates key autophagy markers such as Beclin-1 and ATG5, and enhances the conversion of LC3-I to LC3-II., Apoptosis inducer 50 arrests cancer cells in the G1/S phase by upregulating the expression of p21 and p27 while downregulating Cyclin D1. Apoptosis inducer 50 increases the level of ROS .
    Apoptosis inducer 50
  • HY-162688

    Telomerase G-quadruplex Apoptosis Ferroptosis Others
    Anticancer agent 239 (Compound 5) is a ligand of hTERT promoter G-quadruplex DNA structures (hTERT G4) (Kd = 1.1 μM), and downregulates hTERT expression. Anticancer agent 239 decreases telomerase activity, shortens telomere length, and induces DNA damage, acute cellular senescence, and apoptosis. Anticancer agent 239 causes mitochondrial dysfunction, disrupts iron metabolism and activates ferroptosis in cancer cells. Anticancer agent 239 inhibits tumor growth in MDA-MB-231 xenograft mouse model .
    Anticancer agent 239
  • HY-181665

    Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) Apoptosis Neurological Disease
    Ferroptosis-IN-23 is an inhibitor of ferroptosis. Ferroptosis-IN-23 exerts a synergistic effect by simultaneously activating Steap4 and glutathione peroxidase 4 (GPX4), thereby maintaining iron metabolism homeostasis. Ferroptosis-IN-23 reverses neuronal ferroptosis and inhibits lipid ROS accumulation in cells. Ferroptosis-IN-23 inhibits ferroptosis in zebrafish, alleviates neuronal apoptosis, ROS accumulation, and dopaminergic neuron damage in a zebrafish model of Parkinson's disease. Ferroptosis-IN-23 can be used for research on Parkinson's disease .
    Ferroptosis-IN-23

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: